Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression

Abstract

Analysis of data obtained during the VREMYA trial showed that combined use of the melatoninergic antidepressant Valdoxan with antidepressants of other groups is highly effective in treating moderate and severe forms of nonpsychotic depression without producing serious adverse events. The author believes that this provides grounds for proposing that this combination of agents be used in the treatment of refractory affective disorders.